203 related articles for article (PubMed ID: 33164941)
1. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.
McGarry A; Leinonen M; Kieburtz K; Geva M; Olanow CW; Hayden M
J Huntingtons Dis; 2020; 9(4):371-380. PubMed ID: 33164941
[TBL] [Abstract][Full Text] [Related]
2. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
McGarry A; Auinger P; Kieburtz K; Geva M; Mehra M; Abler V; Grachev ID; Gordon MF; Savola JM; Gandhi S; Papapetropoulos S; Hayden M
J Huntingtons Dis; 2020; 9(2):173-184. PubMed ID: 32508327
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
[TBL] [Abstract][Full Text] [Related]
4. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M
J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
Huntington Study Group HART Investigators
Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
[TBL] [Abstract][Full Text] [Related]
6. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
[TBL] [Abstract][Full Text] [Related]
7. The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.
Naia L; Ly P; Mota SI; Lopes C; Maranga C; Coelho P; Gershoni-Emek N; Ankarcrona M; Geva M; Hayden MR; Rego AC
Neurotherapeutics; 2021 Apr; 18(2):1017-1038. PubMed ID: 33797036
[TBL] [Abstract][Full Text] [Related]
8. Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose.
Darpo B; Geva M; Ferber G; Goldberg YP; Cruz-Herranz A; Mehra M; Kovacs R; Hayden MR
Neurol Ther; 2023 Apr; 12(2):597-617. PubMed ID: 36811812
[TBL] [Abstract][Full Text] [Related]
9. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
Ryskamp D; Wu J; Geva M; Kusko R; Grossman I; Hayden M; Bezprozvanny I
Neurobiol Dis; 2017 Jan; 97(Pt A):46-59. PubMed ID: 27818324
[TBL] [Abstract][Full Text] [Related]
10. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
Squitieri F; de Yebenes JG
Drug Des Devel Ther; 2015; 9():5827-33. PubMed ID: 26604684
[TBL] [Abstract][Full Text] [Related]
11. Rate of functional decline in Huntington's disease. Huntington Study Group.
Marder K; Zhao H; Myers RH; Cudkowicz M; Kayson E; Kieburtz K; Orme C; Paulsen J; Penney JB; Siemers E; Shoulson I
Neurology; 2000 Jan; 54(2):452-8. PubMed ID: 10668713
[TBL] [Abstract][Full Text] [Related]
12. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
[TBL] [Abstract][Full Text] [Related]
13. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
Waters S; Tedroff J; Ponten H; Klamer D; Sonesson C; Waters N
J Huntingtons Dis; 2018; 7(1):1-16. PubMed ID: 29480206
[TBL] [Abstract][Full Text] [Related]
14. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
Garcia-Miralles M; Geva M; Tan JY; Yusof NABM; Cha Y; Kusko R; Tan LJ; Xu X; Grossman I; Orbach A; Hayden MR; Pouladi MA
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212949
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
Lundin A; Dietrichs E; Haghighi S; Göller ML; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
Clin Neuropharmacol; 2010; 33(5):260-4. PubMed ID: 20616707
[TBL] [Abstract][Full Text] [Related]
16. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
[TBL] [Abstract][Full Text] [Related]
17. Pridopidine for the treatment of Huntington's disease.
Shannon KM
Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
[TBL] [Abstract][Full Text] [Related]
18. The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.
Rabinovich-Guilatt L; Siegler KE; Schultz A; Halabi A; Rembratt A; Spiegelstein O
Br J Clin Pharmacol; 2016 Feb; 81(2):246-55. PubMed ID: 26407011
[TBL] [Abstract][Full Text] [Related]
19. A futility study of minocycline in Huntington's disease.
Huntington Study Group DOMINO Investigators
Mov Disord; 2010 Oct; 25(13):2219-24. PubMed ID: 20721920
[TBL] [Abstract][Full Text] [Related]
20. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
Kusko R; Dreymann J; Ross J; Cha Y; Escalante-Chong R; Garcia-Miralles M; Tan LJ; Burczynski ME; Zeskind B; Laifenfeld D; Pouladi M; Geva M; Grossman I; Hayden MR
Mol Neurodegener; 2018 May; 13(1):25. PubMed ID: 29783994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
